Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $50.46 down -3.61% from its previous closing price of $52.35. In other words, the price has decreased by -$3.61 from its previous closing price. On the day, 1.18 million shares were traded. MLTX stock price reached its highest trading level at $52.57 during the session, while it also had its lowest trading level at $46.265.
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rothschild & Co Redburn on July 28, 2025, initiated with a Neutral rating and assigned the stock a target price of $65.
On May 19, 2025, Wolfe Research Upgraded its rating to Outperform which previously was Peer Perform but kept the price unchanged to $61.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $67 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 03 ’25 when Moukheibir Catherine sold 23,500 shares for $48.79 per share. The transaction valued at 1,146,565 led to the insider holds 0 shares of the business.
Moukheibir Catherine bought 23,500 shares of MLTX for $1,146,595 on Jul 03 ’25. On Oct 04 ’24, another insider, BVF PARTNERS L P/IL, who serves as the Director of the company, sold 2,000,000 shares for $50.00 each. As a result, the insider received 100,003,200 and left with 1,287,768 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 3202913024 and an Enterprise Value of 2803437824.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.27, which has changed by 0.20000005 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $58.26, while it has fallen to a 52-week low of $31.42. The 50-Day Moving Average of the stock is 7.87%, while the 200-Day Moving Average is calculated to be 10.99%.
Shares Statistics:
For the past three months, MLTX has traded an average of 506.05K shares per day and 506420 over the past ten days. A total of 63.47M shares are outstanding, with a floating share count of 52.94M. Insiders hold about 16.60% of the company’s shares, while institutions hold 94.37% stake in the company. Shares short for MLTX as of 1752537600 were 6344466 with a Short Ratio of 12.54, compared to 1749772800 on 6118052. Therefore, it implies a Short% of Shares Outstanding of 6344466 and a Short% of Float of 22.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of MoonLake Immunotherapeutics (MLTX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.72 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$2.72 and -$3.14 for the fiscal current year, implying an average EPS of -$2.92. EPS for the following year is -$3.54, with 8.0 analysts recommending between -$1.83 and -$4.07.
